weight loss response to semaglutide in postmenopausal women for Menopause Loss: Clinical Evidence – PlexusDx Woman shares journey of weight

The global GLP-1 Weight Loss Drug Market was valued at USD 68.65 billion in 2026 and is projected to reach USD 195.01 billion by 2035 , growing at a CAGR of 12.3% during the 20262035 forecast period

Case Studies: 68-week clinical study findings on the effectiveness of Semaglutide (2024): Total average weight loss of 15.8%, of the participants demonstrating the significant impact of semaglutide on weight mgmt 50% of the participants experienced a reduction equivalent to 15% of their initial body weight

Also, if you eat a larger-than-normal meal, which youre prone to doing after not eating for many hours, you may upset your stomach

Semaglutide is delivered via weekly subcutaneous injections, meaning its injected under the skin once a week

The active ingredient belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class

doi: 10.2337/dc14-1958 209 GallwitzBVaagAFalahatiAMadsbadS